Abstract | PURPOSE OF REVIEW: Summarize evidence on Developmental and Epileptic Encephalopathies (DEEs) treatments focusing on new and emerging pharmacologic therapies (see Video, http://links.lww.com/CONR/A61, Supplementary Digital Content 1, which provides an overview of the review). RECENT FINDINGS: SUMMARY: Development of new therapies promise to address unmet needs for patients with DEEs, including improvement of neurocognitive function and quality of life.
|
Authors | Alejandra Vasquez, Ersida Buraniqi, Elaine C Wirrell |
Journal | Current opinion in neurology
(Curr Opin Neurol)
Vol. 35
Issue 2
Pg. 145-154
(04 01 2022)
ISSN: 1473-6551 [Electronic] England |
PMID | 35102126
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Anticonvulsants
- Fenfluramine
|
Topics |
- Anticonvulsants
(therapeutic use)
- Epilepsies, Myoclonic
(chemically induced, drug therapy)
- Fenfluramine
(pharmacology, therapeutic use)
- Humans
- Lennox Gastaut Syndrome
(drug therapy)
- Quality of Life
|